General Healthcare

Filter

Breaking Barriers in Cervical Cancer Screening for LGBTQ+ AFAB Individuals

August 2025

New research highlights how outdated cervical cancer screening guidelines in the U.S. fail to meet the needs of sexual and gender minoritized (SGM) people assigned female at birth.

EMJ

Norgine Completes Agreement With Aspen For Its Southern African Operations And Product Rights

London. 30 September 2015, 14:00 BST. Norgine B.V. today announced that it has completed its agreement with Pharmacare Limited, a wholly owned subsidiary…

EMJ

Lifestyle Intervention Programme : Multidisciplinary Approach Increased Compliance by 450%

The Specialist Health Centre, an organisation working alongside the Essex primary and secondary care trusts, has recently responded to the demand for…

EMJ

NITID (Optical Coherence Tomography and Digital Dermatoscope Handheld Device) – CE Mark Approval Received

Madrid, September 10, 2015. DermaLumics, a recently founded spin-off of optical tomography systems developer MedLumics, announces that NITID…

EMJ

Janssen Submits European Extension Marketing Authorisation Application for Paliperidone Palmitate Once-Every-Three-Months Formulation

BEERSE, Belgium, 21st August 2015 – Janssen-Cilag International NV (Janssen) today announced the submission of an Extension Marketing Authorisation…

EMJ

European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment

Foster City, CA, August 20, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the company’s Marketing Authorization Application (MAA)…

EMJ

Gilead Announces Phase 3 Results from the First Study to Evaluate Switching from TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)

VANCOUVER, July 21, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48 week data from an open-label Phase 3 study (Study 109)…

EMJ

SENRI Trial Opens Window to Evaluate NK1 Antagonists for Emesis Prevention in Oxaliplatin Chemotherapy

BARCELONA-LUGANO, 1 July 2015 – The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin…

EMJ

Biosense Webster Launches CARTO® 3 System CONFIDENSE™ Module for Optimized High-Density Mapping During Catheter Ablation Procedures

Diamond Bar, Calif., June 18, 2015 – Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today…

Loading posts...

« Previous 1 … 35 36 37 38 39 … 42 Next »